The latest progress in the drug class development is sodium–glucose co-transporter 2 (SGLT2) inhibitors, which took an innovative approach to an age-old problem: to decrease glucose load in patients with diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.